Numerous recalls have been initiated in 2025 due to the potential for damaged products, foodborne illness, contamination and ...

Detailed price information for Intellia Thera CS (NTLA-Q) from The Globe and Mail including charting and trades.

Swiss pharma giant Novartis AGNVS reported better-than-expected results for the second quarter of 2025 and upped annual guidance for core operating income. Core earnings (excluding one-time charges) ...

August 5, 2025Harmony Biosciences Holdings, Inc. misses on earnings expectations. Reported EPS is $0.681 EPS, expectations ...

BAYRY wins FDA nod to expand Kerendia's label, making it the only approved non-steroidal MR antagonist for two major conditions.

Eli Lilly and Company (NYSE:LLY) is one of Goldman Sachs’ top healthcare stock picks. On July 9, the company confirmed the approval by the US Food and Drug Administration of a label update for ...

European and FDA approval of Sephience (sepiapterin) with broad labeling for PKU - - Global launch underway in Europe and U.S. - - Total Q2 Revenue of $179M - ...

The FDA has expanded the label of Bayer’s kidney disease drug Kerendia to include treatment of patients with two types of heart failure.

An FDA expert panel has reignited a decades-old debate over hormone therapy treatment for menopause, as advocates argue over black box warnings and and a controversial 20th-century study.

Bayer AG BAYRY announced that the FDA has approved a label expansion of kidney disease drug Kerendia (finerenone). The regulatory body approved finerenone for the treatment of adult patients with ...

FDA Approves Kisunla Label Update: New titration dosing schedule for Kisunla (donanemab-azbt) reduces risk of amyloid-related imaging abnormalities with edema/effusion (ARIA-E) in early symptomatic ...

The FDA is reconsidering the black box warning on estrogen. Experts say it’s time for a change—find out what this means for hormone therapy and your health.